Last reviewed · How we verify
LAS41008
LAS41008 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.
LAS41008 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Psoriasis, Atopic dermatitis.
At a glance
| Generic name | LAS41008 |
|---|---|
| Also known as | Verum |
| Sponsor | Almirall, S.A. |
| Drug class | PDE4 inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting PDE4, the drug prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to elevated intracellular cAMP concentrations. This suppresses the activation and function of inflammatory cells, particularly T cells and dendritic cells, reducing the production of pro-inflammatory cytokines and chemokines. The mechanism is designed to provide anti-inflammatory and immunomodulatory effects for inflammatory and autoimmune conditions.
Approved indications
- Psoriasis
- Atopic dermatitis
Common side effects
- Nausea
- Diarrhea
- Headache
- Vomiting
Key clinical trials
- Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008 (PHASE1)
- LAS41008 in Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |